

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC,  
Petitioner

v.

CIPLA LTD.,  
Patent Owner

---

Case No. 2020-00368  
U.S. Patent No. 8,163,723

---

**DECLARATION OF MAUREEN D. DONOVAN, PH.D.**

**TABLE OF CONTENTS**

I. Qualifications and Experience ..... 1

II. Materials Considered ..... 3

III. Relevant Legal Standards..... 6

IV. Priority Date of the '723 *Patent* and Level of Ordinary Skill ..... 8

V. Technical Background .....10

    A. Astelin<sup>®</sup> (Azelastine Hydrochloride) Nasal Spray Formulation.....10

        1. Astelin<sup>®</sup> Nasal Spray in *PDR 1999* (Ex. 1010).....10

        2. *Hettche* (Ex. 1013).....11

    B. Flonase<sup>®</sup> (Fluticasone Propionate) Nasal Spray Formulation .....16

        1. Flonase<sup>®</sup> Nasal Spray in *PDR 1999* (Ex. 1010).....16

    C. Co-Formulations Comprising Azelastine and Fluticasone.....17

        1. *Cramer* (Ex. 1011).....17

        2. *Segal* (Ex. 1012) .....23

    D. *Handbook* (Ex. 1032).....26

VI. The Challenged Claims.....31

VII. The Challenged Claims Would Have Been Obvious Over *PDR 1999* in view of *Segal*.....32

    A. Insufflation Powder (Dependent Claim 6).....33

    B. Particle Size (Dependent Claim 11) .....34

    C. Aqueous Suspension (Dependent Claims 12-14).....36

    D. pH (Dependent Claims 22, 23).....37

    E. Surfactant (Dependent Claims 15, 24) .....38

    F. Concentration of Surfactant (Dependent Claim 16).....39

    G. Glycerin (Dependent Claims 17, 25).....40

    H. Preservative (Dependent Claims 20, 26) .....41

    I. Thickening Agent (Dependent Claims 21, 27) .....43

    J. Buffer (Dependent Claim 19).....44

    K. Buffer, Preservative, Suspending Agent, Thickening Agent (Dependent Claim 18).....45

L.	Edetate Disodium, Glycerin, Thickening Agent Comprising Microcrystalline Cellulose and Sodium Carboxymethyl Cellulose, Polysorbate 80, Benzalkonium Chloride, Phenyl Ethyl Alcohol, and Purified Water (Dependent Claim 28).....	45
M.	Reasonable Expectation of Success in Preparing the Claimed Formulations.....	48
VIII.	The Challenged Claims Would Have Been Obvious Over <i>Cramer</i> In View of <i>PDR 1999</i> .....	50
A.	Insufflation Powder (Dependent Claim 6).....	51
B.	Particle Size (Dependent Claim 11) .....	52
C.	Aqueous Suspension (Dependent Claims 12-14).....	53
D.	pH (Dependent Claims 22, 23).....	54
E.	Surfactant (Dependent Claims 15, 24) .....	55
F.	Concentration of Surfactant (Dependent Claim 16).....	57
G.	Glycerin (Dependent Claims 17, 25).....	58
H.	Preservative (Dependent Claims 20, 26) .....	60
I.	Thickening Agent (Dependent Claims 21, 27) .....	62
J.	Buffer (Dependent Claim 19).....	64
K.	Buffer, Preservative, Suspending Agent, Thickening Agent (Dependent Claim 18).....	66
L.	Edetate Disodium, Glycerin, a Thickening Agent Comprising Microcrystalline Cellulose and Sodium Carboxymethyl Cellulose, Polysorbate 80, Benzalkonium Chloride, Phenyl Ethyl Alcohol, and Purified Water (Dependent Claim 28).....	66
M.	Reasonable Expectation of Success in Preparing the Claimed Formulation .....	70
IX.	Operability of Example 3 of <i>Cramer</i> .....	72
X.	Conclusion.....	75

I, Maureen D. Donovan, Ph.D., do hereby declare:

1. I am making this Declaration at the request of GlaxoSmithKline Consumer Healthcare Holdings (US) LLC Consumer Healthcare Holdings (US) LLC (“GSK”) in the matter of *Inter Partes* Review (“IPR”) of U.S. Patent No. 8,163,723 (“’723 Patent”). I understand that the ’723 Patent is owned by Cipla Ltd. (“Patent Owner”) and licensed to Mylan Pharmaceuticals, which acquired Meda Pharmaceuticals.

2. I am being compensated for my work on this matter at my standard consulting rate, which is \$600 per hour for time spent providing testimony, with an eight-hour minimum per day of testimony, and \$400 per hour for time spent on other tasks, such as analyzing documents and drafting declarations. My compensation in no way depends on the outcome of this proceeding or the content of my testimony, and my opinions are based on my own views of the patented technology and the prior art.

## **I. QUALIFICATIONS AND EXPERIENCE**

3. My area of expertise is in the field of pharmaceuticals and nasal formulations. At University of Iowa’s College of Pharmacy, I am presently a Professor in the Department of Pharmaceutical Sciences and Experimental Therapeutics within the Division of Pharmaceutics and Translational Therapeutics.

4. My research areas include the development and evaluation of novel drug delivery systems for mucosal drug delivery especially via the nasal, gastrointestinal and vaginal epithelia. I also study the mechanisms of drug absorption and disposition.

5. I obtained a Bachelor of Science in Pharmacy from the University of Minnesota in 1983 and a Ph.D. in Pharmaceutics from the University of Michigan in 1989.

6. I have previously provided expert opinions about the '723 *Patent* and related U.S. Patent Nos. 8,168,620 (“'620 *Patent*”) and 9,259,428 (“'428 *Patent*”) in a patent infringement litigation. I have also previously provided expert opinions about the '620 *Patent* in a prior IPR proceeding at the U.S. Patent and Trademark Office (“USPTO”). I understand that these matters are captioned and were resolved as follows: (1) *Meda Pharmaceuticals, Inc. v. Apotex Inc.*, No. 14-cv-01453 (D. Del.) (dismissed by stipulation on May 18, 2017) (“the Apotex litigation”); and (2) *Argentum Pharmaceuticals LLC v. Cipla Ltd.*, IPR2017-00807 (PTAB) (terminated by joint motion on May 21, 2018) (“the Argentum IPR”).

7. My curriculum vitae is provided as Appendix A to this Declaration.

8. In view of my experiences and expertise outlined above and provided in my curriculum vitae, I am an expert in the field of pharmaceuticals and nasal formulations.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.